RxDoctor Payments Data

Stacey South, MD

Gynecologic Oncology · Sarasota, FLNPI 1336368547

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (41.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Intuitive Surgical at 56.9% of the total. 2025 is the largest year on record at $8,256, 4.9 times the $1,671 reported in 2019.

$19,525in general payments, 2019–2025

Across 78 payments — averaging $250.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$11K
  • Baxter Healthcare$8K
  • Conmed Corporation$158
  • Covidien LP$100
  • Astellas Pharma US Inc$83
  • Merck$50
  • plus $137 from 5 others

What the payments were for

  • Consulting fees$7,59039%
  • Speaking & faculty fees$6954%
  • Travel & lodging$320%
  • Food & beverage$2,69514%
  • Education$8,08341%
  • Gifts$4312%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,525 in reported general payments places this provider in the 75th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida

Medicare billing

Part B allowed, 2024
$121,289
Medicare patients
274
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol22$1,441
Megestrol Acetate15$954
Metronidazole11$127
Fluconazole13$112

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →